Screening for prostate cancer: An updated review

Expert Review of Anticancer Therapy

Volumn 13, Issue 1, 2013, Pages 101-108

  Marta, Gustavo Nader ^a   Hanna, Samir Abdallah ^a   Da Silva, João Luis Fernandes ^a   De Andrade Carvalho, Heloisa ^a  

^a HOSPITAL SÍRIO LIBANÊS   (Brazil)

Author keywords

cancer screening; diagnoses; examinations; mass screening; neoplasms; prostate; prostate cancer; prostatic specific antigen

Indexed keywords

ANDROSTANOLONE; DUTASTERIDE; FINASTERIDE; PROSTATE SPECIFIC ANTIGEN;

AGE; ANTIGEN DETECTION; BLOOD LEVEL; BODY MASS; CANCER CHEMOTHERAPY; CANCER GRADING; CANCER MORTALITY; CANCER RISK; CANCER SCREENING; DIAGNOSTIC VALUE; DIFFERENTIAL DIAGNOSIS; DIGITAL RECTAL EXAMINATION; DISEASE ASSOCIATION; HORMONE ACTION; HORMONE SYNTHESIS; HUMAN; IMMUNOASSAY; MEDICAL DECISION MAKING; PREDICTION; PROSTATE CANCER; PROSTATE HYPERTROPHY; QUALITY OF LIFE; RACE DIFFERENCE; REVIEW; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; TREATMENT DURATION; VELOCITY;

AGE FACTORS; EARLY DETECTION OF CANCER; HUMANS; INCIDENCE; LIFE EXPECTANCY; MALE; MASS SCREENING; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS;

EID: 84871532375     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/era.12.154     Document Type: Review

References (84)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J. Clin. 61(2), 69-90 (2011).
2. Eble JN, Sauter G, Epstein JI. Pathology and Genetics of Tumours of the Urinary System and Male Genital Organs: WHO Classification of Tumours. IARC Press, Lyon, France, 162-215 (2004).
3. Siegel R, Ward E, Brawley O, Jemal A. Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA. Cancer J. Clin. 61(4), 212-236 (2011).
4. Swerdlow AJ, Marmot MG, Grulich AE, Head J. Cancer mortality in Indian and British ethnic immigrants from the Indian subcontinent to England and Wales. Br. J. Cancer 72(5), 1312-1319 (1995).
5. Grulich AE, Swerdlow AJ, Head J, Marmot MG. Cancer mortality in African and Caribbean migrants to England and Wales. Br. J. Cancer 66(5), 905-911 (1992).
6. Breslow N, Chan CW, Dhom G et al. Latent carcinoma of prostate at autopsy in seven areas. The International Agency for Research on Cancer, Lyons, France. Int. J. Cancer 20(5), 680-688 (1977).
7. Catalona WJ, Smith DS, Ratliff TL, Basler JW. Detection of organ-confined prostate cancer is increased through prostate-specific antigen-based screening. JAMA 270(8), 948-954 (1993).
8. Dorr VJ, Williamson SK, Stephens RL. An evaluation of prostate-specific antigen as a screening test for prostate cancer. Arch. Intern. Med. 153(22), 2529-2537 (1993).
9. Diamandis EP. Prostate-specific antigen: a cancer fighter and a valuable messenger? Clin. Chem. 46(7), 896-900 (2000).
10. Tenke P, Horti J, Balint P, Kovacs B. Prostate cancer screening. Recent Results Cancer Res. 175, 65-81 (2007).
11. Hudson MA, Bahnson RR, Catalona WJ. Clinical use of prostate specific antigen in patients with prostate cancer. J. Urol. 142(4), 1011-1017 (1989).
12. Tchetgen MB, Song JT, Strawderman M, Jacobsen SJ, Oesterling JE. Ejaculation increases the serum prostate-specific antigen concentration. Urology 47(4), 511-516 (1996).
13. Herschman JD, Smith DS, Catalona WJ. Effect of ejaculation on serum total and free prostate-specific antigen concentrations. Urology 50(2), 239-243 (1997).
14. Simardi LH, Tobias-MacHado M, Kappaz GT, Taschner Goldenstein P, Potts JM, Wroclawski ER. Influence of asymptomatic histologic prostatitis on serum prostatespecific antigen: a prospective study. Urology 64(6), 1098-1101 (2004).
15. Kawakami J, Siemens DR, Nickel JC. Prostatitis and prostate cancer: implications for prostate cancer screening. Urology 64(6), 1075-1080 (2004).
16. Andruss CM, Dinella TJ, Macpherson DS et al. Effect of digital rectal examination on serum prostate-specific antigen in a primary care setting: the Internal Medicine Clinic Research Consortium. Arch. Intern. Med. 155, 389-392 (1995).
17. Chybowski FM, Bergstralh EJ, Oesterling JE. The effect of digital rectal examination on the serum prostate specific antigen concentration: results of a randomized study. J. Urol. 148(1), 83-86 (1992).
18. Marberger M, Freedland SJ, Andriole GL et al. Usefulness of prostate-specific antigen (PSA) rise as a marker of prostate cancer in men treated with dutasteride: lessons from the REDUCE study. BJU Int. 109(8), 1162-1169 (2012).
19. Andriole GL, Bostwick D, Brawley OW et al.; REDUCE Study Group. The effect of dutasteride on the usefulness of prostate specific antigen for the diagnosis of high grade and clinically relevant prostate cancer in men with a previous negative biopsy: results from the REDUCE study. J. Urol. 185(1), 126-131 (2011).
20. Etzioni RD, Howlader N, Shaw PA et al. Long-term effects of finasteride on prostate specific antigen levels: results from the Prostate Cancer Prevention Trial. J. Urol. 174(3), 877-881 (2005).
21. D'Amico AV, Roehrborn CG. Effect of 1 mg/day finasteride on concentrations of serum prostate-specific antigen in men with androgenic alopecia: a randomised controlled trial. Lancet Oncol. 8(1), 21-25 (2007).
22. Guess HA, Gormley GJ, Stoner E, Oesterling JE. The effect of finasteride on prostate specific antigen: review of available data. J. Urol. 155(1), 3-9 (1996).
23. Wang LG, Liu XM, Kreis W, Budman DR. Down-regulation of prostate-specific antigen expression by finasteride through inhibition of complex formation between androgen receptor and steroid receptorbinding consensus in the promoter of the PSA gene in LNCaP cells. Cancer Res. 57(4), 714-719 (1997).
24. Debruyne F. Hormonal therapy of prostate cancer. Semin. Urol. Oncol. 20(3 Suppl 1), 4-9 (2002).
25. Andriole GL, Guess HA, Epstein JI et al. Treatment with finasteride preserves usefulness of prostate-specific antigen in the detection of prostate cancer: results of a randomized, double-blind, placebo-controlled clinical trial. PLESS Study Group. Proscar Long-term Efficacy and Safety Study. Urology 52(2), 195-201; discussion 201 (1998).
26. Roehrborn CG, Marks LS, Fenter T et al. Efficacy and safety of dutasteride in the four-year treatment of men with benign prostatic hyperplasia. Urology 63(4), 709-715 (2004).
27. Guess HA, Heyse JF, Gormley GJ. The effect of finasteride on prostate-specific antigen in men with benign prostatic hyperplasia. Prostate 22(1), 31-37 (1993).
28. Marks LS, Andriole GL, Fitzpatrick JM, Schulman CC, Roehrborn CG. The interpretation of serum prostate specific antigen in men receiving 5alpha-reductase inhibitors: a review and clinical recommendations. J. Urol. 176(3), 868-874 (2006).
29. Modi P, Helfand BT, McVary KT. Medications and surgical interventions for benign prostatic hyperplasia are potential confounders of prostate-specific antigen. Curr. Urol. Rep. 11(4), 224-227 (2010).
30. Mondul AM, Selvin E, De Marzo AM, Freedland SJ, Platz EA. Statin drugs, serum cholesterol, and prostate-specific antigen in the National Health and Nutrition Examination Survey 2001-2004. Cancer Causes Control 21(5), 671-678 (2010).
31. Hamilton RJ, Goldberg KC, Platz EA, Freedland SJ. The influence of statin medications on prostate-specific antigen levels. J. Natl. Cancer Inst. 100(21), 1511-1518 (2008).
32. Chang SL, Harshman LC, Presti JC Jr. Impact of common medications on serum total prostate-specific antigen levels: analysis of the National Health and Nutrition Examination Survey. J. Clin. Oncol. 28(25), 3951-3957 (2010).
33. Singer EA, Palapattu GS, van Wijngaarden E. Prostate-specific antigen levels in relation to consumption of nonsteroidal anti-inflammatory drugs and acetaminophen: results from the 2001-2002 National Health and Nutrition Examination Survey. Cancer 113(8), 2053-2057 (2008).
34. Lin YH, Chen CL, Hou CP, Chang PL, Tsui KH. A comparison of androgen deprivation therapy versus surgical castration for patients with advanced prostatic carcinoma. Acta Pharmacol. Sin. 32(4), 537-542 (2011).
35. Crawford ED. Prostate Cancer Awareness Week: September 22 to 28, 1997. CA. Cancer J. Clin. 47(5), 288-296 (1997).
36. Morgan TO, Jacobsen SJ, McCarthy WF, Jacobson DJ, McLeod DG, Moul JW. Age-specific reference ranges for prostatespecific antigen in black men. N. Engl. J. Med. 335(5), 304-310 (1996).
37. Oesterling JE, Jacobsen SJ, Chute CG et al. Serum prostate-specific antigen in a community-based population of healthy men: establishment of age-specific reference ranges. JAMA 270(7), 860-864 (1993).
38. Rundle A, Neugut AI. Obesity and screening PSA levels among men undergoing an annual physical exam. Prostate 68(4), 373-380 (2008).
39. Baillargeon J, Pollock BH, Kristal AR et al. The association of body mass index and prostate-specific antigen in a populationbased study. Cancer 103(5), 1092-1095 (2005).
40. Beebe-Dimmer JL, Faerber GJ, Morgenstern H et al. Body composition and serum prostate-specific antigen: review and findings from Flint Men's Health Study. Urology 71(4), 554-560 (2008).
41. Werny DM, Thompson T, Saraiya M et al. Obesity is negatively associated with prostate-specific antigen in US men, 2001-2004. Cancer Epidemiol. Biomarkers Prev. 16(1), 70-76 (2007).
42. Brawer MK, Chetner MP, Beatie J, Buchner DM, Vessella RL, Lange PH. Screening for prostatic carcinoma with prostate specific antigen. J. Urol. 147(3 Pt 2), 841-845 (1992).
43. Mettlin C, Lee F, Drago J, Murphy GP. The American Cancer Society National Prostate Cancer Detection Project: findings on the detection of early prostate cancer in 2425 men. Cancer 67(12), 2949-2958 (1991).
44. Crawford ED, DeAntoni EP, Etzioni R, Schaefer VC, Olson RM, Ross CA. Serum prostate-specific antigen and digital rectal examination for early detection of prostate cancer in a national community-based program. The Prostate Cancer Education Council. Urology 47(6), 863-869 (1996).
45. Wolf AM, Wender RC, Etzioni RB et al.; American Cancer Society Prostate Cancer Advisory Committee. American Cancer Society guideline for the early detection of prostate cancer: update 2010. CA. Cancer J. Clin. 60(2), 70-98 (2010).
46. Thompson IM, Pauler DK, Goodman PJ et al. Prevalence of prostate cancer among men with a prostate-specific antigen level or =4.0 ng per milliliter. N. Engl. J. Med. 350(22), 2239-2246, 2004.
47. Catalona WJ, Smith DS, Ornstein DK. Prostate cancer detection in men with serum PSA concentrations of 2.6 to 4.0 ng/mL and benign prostate examination. Enhancement of specificity with free PSA measurements. JAMA 277(18), 1452-1455 (1997).
48. Coley CM, Barry MJ, Fleming C, Mulley AG. Early detection of prostate cancer. Part I: Prior probability and effectiveness of tests. The American College of Physicians. Ann. Intern. Med. 126(5), 394-406 (1997).
49. Strittmatter F, Stieber P, Nagel D et al. Detection of prostate cancer with complexed PSA and complexed/total PSA ratio-is there any advantage? Eur. J. Med. Res. 16(10), 445-450 (2011).
50. Capitanio U, Perrotte P, Zini L et al. Population-based analysis of normal total PSA and percentage of free/total PSA values: results from screening cohort. Urology 73(6), 1323-1327 (2009).
51. Chun FK, Hutterer GC, Perrotte P et al. Distribution of prostate specific antigen (PSA) and percentage free PSA in a contemporary screening cohort with no evidence of prostate cancer. BJU Int. 100(1), 37-41 (2007).
52. Tamimi W, Dafterdar R, Mansi M, Alsaad K, Alarifi SA. Complexed and total PSA in patients with benign prostatic hyperplasia and prostate cancer. Br. J. Biomed. Sci. 67(4), 184-188 (2010).
53. Froehner M, Buck LM, Koch R, Hakenberg OW, Wirth MP. Derivatives of prostate-specific antigen as predictors of incidental prostate cancer. BJU Int. 104(1), 25-28 (2009).
54. Babaian RJ, Naya Y, Cheli C, Fritsche HA. The detection and potential economic value of complexed prostate specific antigen as a first line test. J. Urol. 175(3 Pt 1), 897-901; discussion 901 (2006).
55. Okihara K, Ukimura O, Nakamura T et al. Complexed PSA improves prostate cancer detection: results from a multicenter Japanese clinical trial. Urology 67(2), 328-332 (2006).
56. Carter HB, Pearson JD, Metter EJ et al. Longitudinal evaluation of prostate-specific antigen levels in men with and without prostate disease. JAMA 267(16), 2215-2220 (1992).
57. Vickers AJ, Savage C, O'Brien MF, Lilja H. Systematic review of pretreatment prostate-specific antigen velocity and doubling time as predictors for prostate cancer. J. Clin. Oncol. 27(3), 398-403 (2009).
58. Raaijmakers R, Wildhagen MF, Ito K et al. Prostate-specific antigen change in the European Randomized Study of Screening for Prostate Cancer, section Rotterdam. Urology 63(2), 316-320 (2004).
59. Vickers AJ, Wolters T, Savage CJ et al. Prostate-specific antigen velocity for early detection of prostate cancer: result from a large, representative, population-based cohort. Eur. Urol. 56(5), 753-760 (2009).
60. Etzioni RD, Ankerst DP, Weiss NS, Inoue LY, Thompson IM. Is prostatespecific antigen velocity useful in early detection of prostate cancer? A critical appraisal of the evidence. J. Natl. Cancer Inst. 99(20), 1510-1515 (2007).
61. Catalona WJ, Richie JP, deKernion JB et al. Comparison of prostate specific antigen concentration versus prostate specific antigen density in the early detection of prostate cancer: receiver operating characteristic curves. J. Urol. 152(6 Pt 1), 2031-2036 (1994).
62. Catalona WJ, Partin AW, Slawin KM et al. Use of the percentage of free prostatespecific antigen to enhance differentiation of prostate cancer from benign prostatic disease: a prospective multicenter clinical trial. JAMA 279(19), 1542-1547 (1998).
63. Hoffman RM, Clanon DL, Littenberg B, Frank JJ, Peirce JC. Using the free-to-total prostate-specific antigen ratio to detect prostate cancer in men with nonspecific elevations of prostate-specific antigen levels. J. Gen. Intern. Med. 15(10), 739-748 (2000).
64. Partin AW, Brawer MK, Bartsch G et al. Complexed prostate specific antigen improves specificity for prostate cancer detection: results of a prospective multicenter clinical trial. J. Urol. 170(5), 1787-1791 (2003).
65. Krahn MD, Mahoney JE, Eckman MH, Trachtenberg J, Pauker SG, Detsky AS. Screening for prostate cancer. A decision analytic view. JAMA 272(10), 773-780 (1994).
66. Hoogendam A, Buntinx F, de Vet HC. The diagnostic value of digital rectal examination in primary care screening for prostate cancer: a meta-analysis. Fam. Pract. 16(6), 621-626 (1999).
67. Yamamoto T, Ito K, Ohi M et al. Diagnostic significance of digital rectal examination and transrectal ultrasonography in men with prostate-specific antigen levels of 4 NG/ML or less. Urology 58(6), 994-998 (2001).
68. Gustafsson O, Norming U, Almgård LE et al. Diagnostic methods in the detection of prostate cancer: a study of a randomly selected population of 2400 men. J. Urol. 148(6), 1827-1831 (1992).
69. Pedersen KV, Carlsson P, Varenhorst E, Löfman O, Berglund K. Screening for carcinoma of the prostate by digital rectal examination in a randomly selected population. BMJ 300(6731), 1041-1044 (1990).
70. Muschenheim F, Omarbasha B, Kardjian PM, Mondou EN. Screening for carcinoma of the prostate with prostate specific antigen. Ann. Clin. Lab. Sci. 21(6), 371-380 (1991).
71. Bretton PR. Prostate-specific antigen and digital rectal examination in screening for prostate cancer: a community-based study. South. Med. J. 87(7), 720-723 (1994).
72. Smith RA, von Eschenbach AC, Wender R et al.; ACS Prostate Cancer Advisory Committee, ACS Colorectal Cancer Advisory Committee, ACS Endometrial Cancer Advisory Committee. American Cancer Society guidelines for the early detection of cancer: update of early detection guidelines for prostate, colorectal, and endometrial cancers. Also: update 2001 testing for early lung cancer detection. CA. Cancer J. Clin. 51(1), 38-75; quiz 77 (2001).
73. Catalona WJ, Richie JP, Ahmann FR et al. Comparison of digital rectal examination and serum prostate specific antigen in the early detection of prostate cancer: results of a multicenter clinical trial of 6630 men. J. Urol. 151(5), 1283-1290 (1994).
74. Richie JP, Catalona WJ, Ahmann FR et al. Effect of patient age on early detection of prostate cancer with serum prostate-specific antigen and digital rectal examination. Urology 42(4), 365-374 (1993).
75. Schröder FH, Hugosson J, Roobol MJ et al.; ERSPC Investigators. Screening and prostate-cancer mortality in a randomized European study. N. Engl. J. Med. 360(13), 1320-1328 (2009).
76. Schröder FH, Hugosson J, Roobol MJ et al.; ERSPC Investigators. Prostate-cancer mortality at 11 years of follow-up. N. Engl. J. Med. 366(11), 981-990 (2012).
77. Andriole GL, Crawford ED, Grubb RL 3rd et al.; PLCO Project Team. Mortality results from a randomized prostate-cancer screening trial. N. Engl. J. Med. 360(13), 1310-1319 (2009).
78. Andriole GL, Crawford ED, Grubb RL 3rd et al.; PLCO Project Team. Prostate cancer screening in the randomized Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial: mortality results after 13 years of follow-up. J. Natl. Cancer Inst. 104(2), 125-132 (2012).
79. Moyer VA; U.S. Preventive Services Task Force. Screening for prostate cancer: US Preventive Services Task Force recommendation statement. Ann. Intern. Med. 157(2), 120-134 (2012).
80. Catalona WJ, D'Amico AV, Fitzgibbons WF et al. What the US Preventive Services Task Force missed in its prostate cancer screening recommendation. Ann. Intern. Med. 157(2), 137-138 (2012).
81. Basch E, Oliver TK, Vickers A et al. Screening for prostate cancer with prostate-specific antigen testing: American Society of Clinical Oncology Provisional Clinical Opinion. J. Clin. Oncol. 30(24), 3020-3025 (2012).
82. Heijnsdijk EA, Wever EM, Auvinen A et al. Quality-of-life effects of prostate-specific antigen screening. N. Engl. J. Med. 367(7), 595-605 (2012).
83. Choudhury AD, Eeles R, Freedland SJ et al. The role of genetic markers in the management of prostate cancer. Eur. Urol. 62(4), 577-587 (2012).
84. Hessels D, Schalken JA. The use of PCA3 in the diagnosis of prostate cancer. Nat. Rev. Urol. 6(5), 255-261 (2009).